PMID- 9989124
OWN - NLM
STAT- MEDLINE
DCOM- 19990316
LR  - 20131121
IS  - 0033-3182 (Print)
IS  - 0033-3182 (Linking)
VI  - 40
IP  - 1
DP  - 1999 Jan-Feb
TI  - Major depression and its response to sertraline in primary care vs. psychiatric 
      office practice patients. Results of an open-label trial in Argentina.
PG  - 70-5
AB  - Great strides have been achieved in recent years in the detection and treatment 
      of major depressive disorder (MDD) in primary care settings. Little is known 
      about the types or patients with MDD seen in primary care as compared with those 
      seen in psychiatric office practice. Few studies have compared clinical outcomes 
      after treatment with antidepressants in these two settings. In Argentina, the 
      authors conducted an open-label treatment study of MDD patients in primary care 
      (n = 469) and psychiatric office practice (n = 299). The patients were compared 
      on baseline sociodemographic and clinical variables. These same patients were 
      treated with sertraline 50-100 mg per day for 8 weeks. At baseline, the patients 
      in psychiatric office practice were younger, more likely to abuse alcohol, less 
      likely to have comorbid medical disorders, and more likely to have failed a prior 
      treatment for depression during the current episode. The two groups did not 
      differ significantly on depression severity or in depressive symptom profile on 
      the Hamilton Depression Rating Scale (Ham-D). After 8 weeks of treatment, mean 
      Ham-D scores were reduced comparably in both groups, from about 25 to about 10. 
      Rates of adverse events were 14%-29%, depending on the follow-up interval. 
      Adherence with treatment was high in both groups (over 95%). The patients in 
      primary care and psychiatry office practice are similar in several ways. 
      Significant reductions in depressive symptoms are possible in both settings, in 
      large numbers of patients, by using doses of sertraline in the 50-100 mg range.
FAU - Lyketsos, C G
AU  - Lyketsos CG
AD  - Neuropsychiatry and Memory Group, Johns Hopkins University, Baltimore, MD, USA.
FAU - Taragano, F
AU  - Taragano F
FAU - Treisman, G J
AU  - Treisman GJ
FAU - Paz, J
AU  - Paz J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Psychosomatics
JT  - Psychosomatics
JID - 0376506
RN  - 0 (Antidepressive Agents)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents/adverse effects/*therapeutic use
MH  - Argentina
MH  - Depressive Disorder, Major/diagnosis/*drug therapy/psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Care Team
MH  - Personality Inventory
MH  - Primary Health Care
MH  - Sertraline/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 1999/02/16 00:00
MHDA- 1999/02/16 00:01
CRDT- 1999/02/16 00:00
PHST- 1999/02/16 00:00 [pubmed]
PHST- 1999/02/16 00:01 [medline]
PHST- 1999/02/16 00:00 [entrez]
AID - S0033-3182(99)71274-0 [pii]
AID - 10.1016/S0033-3182(99)71274-0 [doi]
PST - ppublish
SO  - Psychosomatics. 1999 Jan-Feb;40(1):70-5. doi: 10.1016/S0033-3182(99)71274-0.